Few RVO Patients Prescribed Anti-VEGF after Macular Edema Diagnosis
A new assessment shows about 60% of treatment-naive patients are not prescribed the most common drug class within 1 year of secondary edema.
A new assessment shows about 60% of treatment-naive patients are not prescribed the most common drug class within 1 year of secondary edema.
In this review of the month of October, some of the most notable advancements and news in the field of allergy were highlighted.
Week 156 efficacy and safety data from the FINCH 4 study are consistent with that seen in FINCH 1, 2, and 3.
Teva presents 2 findings at Psych Congress 2024: TEV’749’s effects on social function and quality of life in adults with schizophrenia and risperidone adherence patterns.
If approved, HLX14 would follow the first 2 denosumab biosimilar approvals in March 2024.
This interview with Kraft features a discussion regarding her team’s new data from the BATURA study on albuterol for patients’ asthma exacerbations.
This hepatology month in review spotlights hepatic pipeline news, research on treating and eliminating viral hepatitis, and HCPLive’s coverage of ACG 2024.
Despite the number of individuals with MASLD-related HCC without cirrhosis who report a low FIB-4, current care pathways may not identify such patients for additional…
Normothermic machine perfusion in liver transplants improves preservation, reduces early complications, and shows promise in complex cases.
Panelists discuss how patients with chronic spontaneous urticaria (CSU) experience increased rates of depression, sleep disturbances, and absenteeism, significantly impacting their professional life and overall…
New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.